Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth
- 26 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 9 (4), 415-429
- https://doi.org/10.1158/2326-6066.cir-20-0317
Abstract
Metabolic dysregulation is a hallmark of cancer; for instance, many tumors exhibit auxotrophy for various amino acids, such as arginine, as they are unable to meet the demand for these amino acids through endogenous production. This vulnerability can be exploited by employing therapeutic strategies that deplete systemic arginine in order to limit the growth and survival of arginine auxotrophic tumors. Pegzilarginase, a human arginase 1 enzyme engineered to have superior stability and enzymatic activity relative to the native human arginase 1 enzyme, depletes systemic arginine by converting it to ornithine and urea. Therapeutic administration of pegzilarginase in the setting of arginine auxotrophic tumors exerts direct anti-tumor activity by starving the tumor of exogenous arginine. We hypothesized that in addition to this direct effect, pegzilarginase treatment indirectly augments anti-tumor immunity through increased antigen presentation, thus making pegzilarginase a prime candidate for combination therapy with immuno-oncology (I-O) agents. Indeed, tumor-bearing mice (CT26; MC38; MCA-205) receiving pegzilarginase in combination with aPD-L1 or agonist aOX40 mAb experienced significantly increased survival relative to animals receiving I-O monotherapy. Combination pegzilarginase/immunotherapy induced robust anti-tumor immunity characterized by increased intratumoral effector CD8+ T cells and M1-polarization of tumor-associated macrophages. Our data suggests potential mechanisms of synergy between pegzilarginase and I-O agents that include increased intratumoral MHC expression on both APCs and tumor cells, and increased presence of M1-like anti-tumor macrophages. These data support the clinical evaluation of I-O agents in conjunction with pegzilarginase for the treatment of patients with cancer.Keywords
Other Versions
Funding Information
- CPRIT (DP140031)
This publication has 47 references indexed in Scilit:
- Cytotoxicity of Tumor Antigen Specific Human T Cells Is Unimpaired by Arginine DepletionPLOS ONE, 2013
- Metabolic Regulation of T LymphocytesAnnual Review of Immunology, 2013
- A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cellsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012
- Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytesInternational Immunology, 2012
- IL-10 Elicits IFNγ-Dependent Tumor Immune SurveillanceCancer Cell, 2011
- A New Method for Isolation of Interstitial Fluid from Human Solid Tumors Applied to Proteomic Analysis of Ovarian Carcinoma TissuePLOS ONE, 2011
- Replacing Mn2+ with Co2+ in Human Arginase I Enhances Cytotoxicity toward l-Arginine Auxotrophic Cancer Cell LinesACS Chemical Biology, 2010
- l-arginine availability regulates T-lymphocyte cell-cycle progressionBlood, 2006
- Argininosuccinate synthetase from the urea cycle to the citrulline–NO cycleJBIC Journal of Biological Inorganic Chemistry, 2003
- Regulation of T Cell Receptor CD3ζ Chain Expression byl-ArginineJournal of Biological Chemistry, 2002